News

New institutional investors and family offices participated in the financing alongside original commitments from founding investors MPM Capital and F2 Ventures. Following the completion of the fundraising, Tim

The partnership will combine Accent’s expertise in the biology, target identification and drug discovery of RMP-targeting therapies with AstraZeneca’s advanced knowledge in oncology. Accent Therapeutics CEO Shakti Narayan

Guselkumab is currently not licensed for the treatment of PsA and is undergoing evaluation for this use by the European Medicines Agency (EMA). Data from the two studies

The research is led by infectious disease clinician George Sakoulas, M.D. of Sharp Memorial Hospital and the Sharp Rees-Stealy Medical Group in San Diego, Calif., and Associate Professor

The approval, which is based on results from the phase 3 BEACON CRC trial, enables to market Braftovi plus cetuximab in 27 EU member states, as well as

The approval of Sarclisa and pom-dex combination is for people who had at least two prior therapies including lenalidomide and a proteasome inhibitor and have shown disease progression

True North met both primary endpoints, demonstrating highly statistically significant (p-value < 0.0001) results for induction of clinical remission at Week 10 and in maintenance at Week 52.

AgeX and ImStem are co-operating to finalize financial terms and other provisions of a license agreement. ImStem has previously used AgeX ESI 053 to derive the ImStem IMS001

The regulator has provided the company with the permission to submit an investigational new drug application (IND) to use FSD-201 for the treatment of Covid-19, the disease resulted